Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of EBT Margin readings, the most recent being 15.25% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 396.0% to 15.25% in Q1 2026 year-over-year; TTM through Mar 2026 was 14.06%, a 1377.0% increase, with the full-year FY2025 number at 13.12%, up 1984.0% from a year prior.
  • EBT Margin hit 15.25% in Q1 2026 for Kiniksa Pharmaceuticals International, up from 11.51% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 59.51% in Q4 2022 to a low of 86.37% in Q4 2023.
  • Median EBT Margin over the past 5 years was 1.73% (2023), compared with a mean of 7.02%.
  • Biggest five-year swings in EBT Margin: surged 45491bps in 2022 and later plummeted -14588bps in 2023.
  • Kiniksa Pharmaceuticals International's EBT Margin stood at 59.51% in 2022, then crashed by -245bps to 86.37% in 2023, then surged by 91bps to 7.59% in 2024, then surged by 252bps to 11.51% in 2025, then skyrocketed by 32bps to 15.25% in 2026.
  • The last three reported values for EBT Margin were 15.25% (Q1 2026), 11.51% (Q4 2025), and 15.02% (Q3 2025) per Business Quant data.